Adherence and health care costs with single-pill fixed-dose combinations in hypertension management

Journal of Managed Care Pharmacy

Volumn 20, Issue 1, 2014, Pages 93-100

  Hilleman, Daniel E ^a   Pharm, D ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; DRUG COMBINATION; DRUG COST; HEALTH CARE COST; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; PILL;

ANTIHYPERTENSIVE AGENTS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; HYPERTENSION; MEDICATION ADHERENCE;

EID: 84890870566     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.1.93     Document Type: Article

References (61)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52. Available at: http://hyper.ahajournals.org/content/42/6/1206.full.pdf+html. Accessed August 19, 2013.
2. Centers for Disease Control and Prevention. Vital signs: awareness and treatment of uncontrolled hypertension among adults-United States, 2003-2010. MMWR Morb Mortal Wkly Rep. 2012;61(35):703-09. Available at: http://www.cdc.gov/mmwr/pdf/wk/mm6135.pdf. Accessed August 19, 2013.
3. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics- 2013 update-a report from the American Heart Association. Circulation. 2013;127(1):143-52.
4. Guo F, He D, Zhang W, Walton RG. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol. 2012;60(7):599-606.
5. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010. Circulation. 2012;126(17):2105-14. Available at: http://circ.ahajournals.org/content/126/17/2105.full.pdf+html. Accessed August 19, 2013.
6. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44. Available at: http://circ.ahajournals.org/content/123/8/933.full.pdf+html. Accessed August 19, 2013.
7. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1524-6175.2002.02045.x/pdf. Accessed August 19, 2013.
8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31.
9. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
10. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/1933-1711/PIIS1933171110000069.pdf. Accessed August 19, 2013.
11. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12(11):869-Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2010.00360.x/pdf. Accessed August 19, 2013.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
13. Chapman N, Chang CL, DahlÖf B, Sever PS, Wedel H, Poulter NR. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118(1):42-48. Available at: http://circ.ahajournals.org/content/118/1/42.full.pdf+html. Accessed August 19, 2013.
14. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens. 2008;2(4):294-302.
15. Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009;23(7):479-89.
16. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 Expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2011;57(20):2037-114. Available at: http://ac.els-cdn.com/S0735109711001768/1-s2.0-S0735109711001768-main. pdf?_tid=e22167d0-81ae-11e2-a15e-00000aab0f02&acdnat=1362060069_ a7f9a006db66030d3aafee2403ab7da8. Accessed August 19, 2013.
17. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124-31.
18. Rabbani A, Alexander GC. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens. 2008;21(5):509-13. Available at: http://ajh.oxfordjournals.org/content/21/5/509.full.pdf+html. Accessed August 19, 2013.
19. Malesker MA, Hilleman DE. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Manag Care. 2010;19(7):36-42. Available at: http://www.managedcaremag.com/sites/default/files/imported/1007/1007.peer_combo.pdf. Accessed August 19, 2013.
20. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12(3):243-49.
21. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3(6):999-1005. Available at: http://www.dovepress.com/articles.php?article_id=1565. Accessed August 19, 2013.
22. Hill MN, Miller NH, DeGeest S. ASH position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12(10):757-64. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2010.00356.x/pdf. Accessed August 19, 2013.
23. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239-45. Available at: http://amcp.org/data/jmcp/Research_239-245.pdf.
24. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114-17. Available at: http://www.bmj.com/highwire/filestream/366772/field_highwire_article_ pdf/0/1114. Accessed August 19, 2013.
25. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and health care cost. Med Care. 2005;43(6):521-30.
26. Hess G, Hill J, Lau H, Dastani H, Chaudhari P. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P&T. 2008;33(11):652-66. Available at: http://www.ptcommunity.com/ptJournal/fulltext/33/11/PTJ3311652.pdf. Accessed August 19, 2013.
27. Cherry SB, Benner JS, Hussein MA, Tang SS, Nichol MB. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009;12(4):489-97. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/1098-3015/PIIS1098301510607917.pdf. Accessed August 19, 2013.
28. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-605. Available at: http://circ.ahajournals.org/content/120/16/1598.full.pdf+html. Accessed August 19, 2013.
29. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610-18.
30. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418-25.
31. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent health care utilization and costs. Am J Manag Care. 2010;16(8):568-76.
32. Butler RJ, Davis TK, Johnson WG, Gardner HH. Effects of nonadherence with prescription drugs among older adults. Am J Manag Care. 2011;17(2):153-60.
33. Yang W, Kahler KH, Fellers T, et al. Copayment level, treatment persistence, and health care utilization in hypertension patients treated with single-pill combination therapy. J Med Econ. 2011;14(3):267-78.
34. Pesa JA, Van Den Bos J, Gray T, et al. An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures. Patient Prefer Adherence. 2012;6:63-72. Available at: http://www.dovepress.com/an-evaluation-of-theimpact-of-patient-cost-sharing-for-antihypertensi-peer-reviewed-article-PPA. Accessed August 19, 2013.
35. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29(5):972-84.
36. Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814-22.
37. Hilleman DE, Bakris GL. Approaches to achieve blood pressure goals. In: Bakris G, ed. The Kidney and Hypertension. London: Martin Dunitz; 2004:91-103.
38. Oliva RV, Bakris GL. Combination therapy in hypertension. In: Bakris GL, ed. The Kidney in Heart Failure. New York: Springer Science+Business Media; 2012:169-82.
39. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-19. Available at: http://download.journals.elsevierhealth. com/pdfs/journals/0002-9343/PIIS000293430601151X.pdf. Accessed August 19, 2013.
40. Brixner DI, Jackson KC, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin. 2008;24(9):2597-607.
41. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407. Available at: http://hyper.ahajournals.org/content/55/2/399.full.pdf+html. Accessed August 19, 2013.
42. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26(9):2065-76.
43. Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin. 2010;26(12):2877-87.
44. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs freeequivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens. 2011;13(12):898-909. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00550.x/pdf. Accessed August 19, 2013.
45. Kumagai N, Onishi K, Hoshino K, et al. Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. Clin Exp Hypertens. 2013;35(5):55-60.
46. Ferrario CM, Panjabi S, Buzinec P, Swindle JP. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis. 2013;7(1):27-39.
47. Angeli F, Reboldi G, Mazzotta G, et al. Fixed-dose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev. 2012;19(2):51-54.
48. Hilleman DE. Pharmacoeconomics of combination antihypertensive therapy. Blood Press Monit. 2001;6(Suppl 1):S31-S36.
49. Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213-20. Available at: http://stroke.ahajournals.org/content/40/1/213.full.pdf+html. Accessed August 19, 2013.
50. Bailey JE, Wan JY, Tang J, Ghani MA, Cushman WC. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med. 2010;25(6):495-503.
51. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ. 2012;15(5):897-905.
52. Taylor AA, Shiheiber OF. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9(6):324-32. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-5299.2003.03269.x/pdf. Accessed August 19, 2013.
53. Lynch WD, Markosyan K, Melkonian AK, Pesa J, Kleinman NL. Effect of antihypertensive medication adherence among employees with hypertension. Am J Manag Care. 2009;15(12):871-80.
54. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8(1):45-50.
55. Dickson M, Plauschinat CA. Racial differences in medication compliance and health care utilization among hypertensive Medicaid recipients: fixeddose vs free-combination treatment. Ethn Dis. 2008;18(2):204-09. Available at: http://www.ishib.org/journal/18-2/ethn-18-02-204.pdf. Accessed August 19, 2013.
56. Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013;7(1):46-60. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/1933-1711/PIIS1933171112002860.pdf. Accessed August 19, 2013.
57. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide. A randomized clinical trial. Hypertension. 2009;54(1):32-39. Available at: http://hyper.ahajournals.org/content/54/1/32.full.pdf+html. Accessed August 19, 2013.
58. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252-69.
59. Lacourciere Y, Taddei S, Konis G, Fang H, Severin T, Zhang J. Clinic and ambulatory blood pressure-lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. J Hypertens. 2012;30(10):2047-55.
60. Kereiakes DJ, Chrysant SG, Izzo JL Jr., et al. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich). 2012;14(3):149-57. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00588.x/pdf. Accessed August 19, 2013.
61. Murray AV, Koenig W, Garcia-Puig J, Patel S, Uddin A, Zhang J. Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. J Clin Hypertens (Greenwich). 2012;14(12):821-27. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2012.00706.x/pdf. Accessed August 19, 2013.